Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 11/20 | 0.44 |
| ▸ | BCHE | P06276 | 10/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3353930 | 0.83 | IDO1 (0.47) | IDO1ACHEBCHEAGXTRAB9A | |
| SCHEMBL7850367 | 0.80 | IDO1 (0.48) | IDO1ACHECYP1A2CYP2A6TAAR1 | |
| SCHEMBL11988887 | 0.79 | IDO1 (0.44) | IDO1ACHEBCHEAGXTRAB9A | |
| SCHEMBL28430892 | 0.77 | IDO1 (0.52) | IDO1ACHEBCHEAGXTRAB9A | |
| SCHEMBL190895 | 0.76 | IDO1 (0.55) | IDO1ACHEBCHEAGXTTAAR1 | |
| SCHEMBL18531376 | 0.76 | BCHE (0.45) | IDO1ACHEBCHEAGXTRAB9A | |
| SCHEMBL2802287 | 0.76 | IDO1 (0.54) | IDO1ACHEBCHEAGXTRAB9A | |
| SCHEMBL915196 | 0.76 | IDO1 (0.54) | IDO1ACHERAB9ACYP1A2CYP2A6 | |
| SCHEMBL8824002 | 0.75 | APP (0.46) | IDO1 | |
| SCHEMBL9195186 | 0.75 | ESR1 (0.48) | IDO1RAB9ATAAR1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107980001-A | Compounds and compositions comprising phosphorothioated oligodeoxynucleotides and methods of use thereof | 希望之城 | 2018-05-01 | — | — | CN | disclosed |
| CN-107074857-A | Method for preparing crystallization organic semiconducting materials | 巴斯夫欧洲公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-107004768-A | Organic semiconductor composition containing a liquid medium | 巴斯夫欧洲公司 | 2017-08-01 | — | — | CN | disclosed |
| US-20150232616-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. | 2015-08-20 | — | — | US | disclosed |
| US-8980326-B2 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8779008-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140170225-A1 | IMMUNOTHERAPY FOR TREATMENT OF AMYLOID-RELATED DISORDERS USING ENCAPSULATED BETA-AMYLOID PEPTIDES | INTEZYNE TECHNOLOGIES INC (US) | 2014-06-19 | — | — | US | disclosed |
| EP-1807436-B1 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | INTEZYNE TECHNOLOGIES INC (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2359862-B1 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES INC (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2006047419-A2 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-05-04 | — | — | WO | disclosed |
| EP-0472987-B1 | Antimicrobial peptides active against plant pathogens, their use and screening methods pertaining thereto | VIRTUAL DRUG DEV INC (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2000078726-A1 | IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000078724-A2 | IMIDAZOLINDERIVATIVES THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-0919566-A2 | Antimicrobial peptides and their use against plant pathogens | ENICHEM S.p.A. (IT) | 1999-06-02 | — | — | EP | disclosed |
| US-5519115-A | BACTERICIDES OR FUNGICIDES | ENICHEM S.P.A. (IT) | 1996-05-21 | — | — | US | disclosed |
| EP-0664316-A1 | Polycarbonate composition having improved resistance to gamma-ray radiation | TEIJIN LIMITED (JP) | 1995-07-26 | — | — | EP | disclosed |
| US-5424395-A | Magainins | ENICHEM S.P.A. (IT) | 1995-06-13 | — | — | US | disclosed |
| EP-0497366-A2 | Antimicrobial peptides and their use against plant pathogens | ENICHEM S.p.A. (IT) | 1992-08-05 | — | — | EP | disclosed |
| EP-0472987-A1 | Antimicrobial peptides active against plant pathogens, their use and screening methods pertaining thereto | ENICHEM S.p.A. (IT) | 1992-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, CLTB, CD47 | IDO1 4616/4885ACHE 3769/4885BCHE 3058/4885 |
| US-20140170225-A1 | IMMUNOTHERAPY FOR TREATMENT OF AMYLOID-RELATED DISORDERS USING ENCAPSULATED BETA-AMYLOID PEPTIDES | IAPP, APP, TTR | IDO1 1649/4885ACHE 567/4885BCHE 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.